Literature DB >> 3129993

Reconstitution of human factor VIII from isolated subunits.

P J Fay1.   

Abstract

Human factor VII heterodimers were fractionated into component heavy and light chains using an anti-light chain specific monoclonal antibody immunosorbant. Neither the light chain nor the heavy chain alone possessed activity. Factor VII activity was reconstituted by recombining the subunits in the presence of Mn2+ or Ca2+. Reconstitution of activity also showed ionic strength dependence suggesting the importance of hydrophobic and electrostatic interactions. All factor VIII heavy chains (93 to 210 kDa) recombined with the 83 kDa light chain as judged by retention of all reconstituted heterodimeric forms by the monoclonal immunosorbant. Maximum specific activity (3 units/micrograms) was obtained at a 1:1 molar ratio of light chain:heavy chain. The presence of von Willebrand factor enhanced the rate of factor VIII reconstitution as much as 5-fold. This effect was both ionic strength-dependent and dose-dependent up to a 25-fold weight excess of von Willebrand factor over factor VIII.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129993     DOI: 10.1016/0003-9861(88)90404-3

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  17 in total

1.  First determination of the secondary structure of purified factor VIII light chain.

Authors:  N Bihoreau; M P Fontaine-Aupart; A Lehegarat; M Desmadril; J M Yon
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

2.  pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2+.

Authors:  Hironao Wakabayashi; Qian Zhou; Keiji Nogami; Charles Ansong; Fatbardha Varfaj; Stephen Miles; Philip J Fay
Journal:  Biochim Biophys Acta       Date:  2006-04-22

3.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

4.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

5.  Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.

Authors:  M Higuchi; S E Antonarakis; L Kasch; J Oldenburg; E Economou-Petersen; K Olek; M Arai; H Inaba; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 6.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

7.  Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

8.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

9.  A Glu113Ala mutation within a factor VIII Ca2+-binding site enhances cofactor interactions in factor Xase.

Authors:  Hironao Wakabayashi; Ya-Chi Su; Syed S Ahmad; Peter N Walsh; Philip J Fay
Journal:  Biochemistry       Date:  2005-08-02       Impact factor: 3.162

10.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.

Authors:  M Burton; H Nakai; P Colosi; J Cunningham; R Mitchell; L Couto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.